Get the Stockscreener App
41.95
2.29%
0.94
After Hours:
42.16
0.21
+0.50%
Moderna Inc stock is traded at $41.95, with a volume of 7.37M.
It is up +2.29% in the last 24 hours and up +22.30% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$41.01
Open:
$41.07
24h Volume:
7.37M
Relative Volume:
0.64
Market Cap:
$16.39B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-4.8053
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-1.41%
1M Performance:
+22.30%
6M Performance:
+60.60%
1Y Performance:
+28.68%
1-Day Range:
$40.17
$42.00
1-Week Range:
$39.50
$44.17
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.95 | 16.02B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Should You Buy Moderna Before Feb. 13? - Nasdaq
Should You Buy Moderna Before Feb. 13? - The Motley Fool
Moderna (MRNA) Laps the Stock Market: Here's Why - Yahoo Finance Australia
How Investors Are Reacting To Moderna (MRNA) Denied Immunity In High-Stakes Vaccine Patent Case - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? - Nasdaq
A Double Blow for Moderna – Seqirus Topples Two mRNA Patent Applications - Pearce IP
1 Stock to Buy, 1 Stock to Sell This Week: Cisco, Moderna - Investing.com Nigeria
Moderna Balances $5b Patent Trial Risk With Oncology Leadership Shift - Yahoo Finance
United StatesGoodwin Advises Moderna On Strategic Collaboration With Recordati To Globally Commercialize Investigational Propionic Acidemia Therapeutic (MRNA-3927) For $50 Million Upfront And Up To $110 Million In - Mondaq
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline - GuruFocus
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Moderna faces $5 billion mRNA patent lawsuit after ‘Star Trek’ ruling - thestreet.com
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock - Yahoo Finance
Moderna (MRNA) Valuation Check As Rare Disease Deal And New Development Chief Refocus Growth Plans - Yahoo Finance
Moderna (MRNA) to Release Quarterly Earnings on Friday - MarketBeat
Morgan Lewis Hires Moderna In-House Pro In Munich - Law360
Defiance adds single stock ETFs tied to Zeta Global, Moderna - Structured Retail Products
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Judge Wolson Issues Key Summary Judgment Ruling on the Eve of Trial in the Arbutus v. Moderna mRNA Vaccine and Lipid Nanoparticle Case - JD Supra
The Escalator: Moderna, Sparrow Pharmaceuticals, Takeda and more - Medical Marketing and Media
Analysts Offer Insights on Healthcare Companies: Merck KGaA (GB:0O14) and Moderna (MRNA) - The Globe and Mail
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Judge Wolson Issues Key Summary Judgment Ruling on Eve of Trial in Arbutus v. Moderna - IPWatchdog.com
Jim Cramer on Moderna: "Even Though the Stock's on the Mend, There Are Many Pharma and Biotech Names That I Like Better" - Finviz
Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better” - Insider Monkey
Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda - Fox Business
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. - Investing News Network
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna's 7-Step Guide to Veeva AI for PromoMats - Veeva
Why The Narrative Around Moderna (MRNA) Is Shifting After Mixed Analyst Updates - Yahoo Finance
Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves - Yahoo Finance
Are Wall Street Analysts Bullish on Moderna Stock? - Barchart.com
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Shreveport Times
How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks - Yahoo Finance
BioNTech Expands Beyond mRNA While Moderna Focuses on mRNA Pipeline Post-Pandemic - geneonline.com
'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit - Law360
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings - GuruFocus
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Jim Cramer on Moderna: “We have to wait and see” - MSN
Spotlight on Moderna: Analyzing the Surge in Options Activity - Benzinga
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43% - simplywall.st
Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline - Yahoo Finance
Is Moderna (MRNA) Pricing Fair After Recent 42.8% Monthly Share Price Jump - Yahoo Finance
Gainers Report: Can Moderna Inc continue delivering strong returnsIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):